☆ 4.1 Letter

Reply: Misidentified Dopamine Agonists Undermine Investigation Into Aripiprazole Link With Impulse Control Disorders

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Problem Gambling Associated with Aripiprazole: A Nested Case-Control Study in a First-Episode Psychosis Program

Olivier Corbeil et al.

Summary: This study found that individuals with first-episode psychosis and a history of gambling are at increased risk of developing problem gambling when receiving aripiprazole. The results emphasize the importance of systematically screening for problem gambling in all individuals with psychotic disorders, as this comorbidity hinders recovery.

CNS DRUGS (2021)

Add to Collection

Article Multidisciplinary Sciences

Increased risk for developing gambling disorder under the treatment with pramipexole, ropinirole, and aripiprazole: A nationwide register study in Sweden

Mirjam Wolfschlag et al.

Summary: This study examines the association between dopaminergic drugs and GD diagnosis, revealing that dopamine agonists and dopamine modulators increase the likelihood of developing GD. Further research should focus on understanding the neurobiology of GD to design more selective dopaminergic medications with fewer side effects.

PLOS ONE (2021)

Add to Collection

Letter Pharmacology & Pharmacy